RxDoctor Payments Data

Goran Rakocevic, MD

Neurology · Charlottesville, VANPI 1265474217

Payments from drug & device makers

$60,592in general payments, 2019–2025

Across 57 payments — averaging $1063.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Catalyst Pharmaceuticals, Inc.$20K
  • Novartis$17K
  • Argenx US, Inc.$9K
  • Alnylam Pharmaceuticals Inc.$5K
  • Amgen$4K
  • Biogen$2K
  • plus $3K from 8 others

What the payments were for

  • Consulting fees$17,68875%
  • Speaking & faculty fees$4672%
  • Travel & lodging$2,59311%
  • Food & beverage$2,83712%
  • Education$00%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,592 in reported general payments places this provider in the 85th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$35,580
Medicare patients
198
Services billed
299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5043$899,005
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5061$583,917
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5028$411,675
HizentraImmun Glob G(Igg)/Pro/Iga 0-5020$278,336
Mycophenolate Mofetil16$10,147
Pyridostigmine Bromide22$6,712
Gabapentin54$1,529
Diclofenac Sodium12$645
Duloxetine Hcl14$369
Clonazepam15$311
Prednisone24$297
Tramadol Hcl44$251
Sodium Chloride0.9 % Sodium Chloride22$235
Diphenhydramine Hcl18$179
Celecoxib13$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen, Hizentra$119$690,01248 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 neurology providers in Virginia.

Other neurology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →